New anticoagulants for thromboprophylaxis after total knee arthroplasty.

Timothy S. Brown, Michael H. Huo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Total knee arthroplasty (TKA) is one of the most common orthopedic procedures in the United States. The number of TKAs is expected to rise significantly over the next 2 decades. One of the most common complications after TKA is venous thromboembolism (VTE), which is potentially fatal. The incidence of VTE is effectively reduced by prophylactic anticoagulants, and clinical guidelines have been developed to improve VTE management. However, current anticoagulants have limitations in terms of efficacy, safety, half-life, ease of administration, and patient adherence. Moreover, these anticoagulants require routine monitoring and dose adjustment, and potential bleeding complications represent an important concern. A new generation of anticoagulants, including recently approved rivaroxaban, is being developed to address the shortcomings of current agents. The efficacy and safety of these newer agents are comparable with those of existing ones. Rivaroxaban is the only new oral agent that is approved for use in TKA and that has demonstrated an efficacy superior to that of enoxaparin in phase 3 trials. To optimize the management of VTE prophylaxis after TKAs, orthopedic surgeons must have a thorough understanding of these new oral agents.

Original languageEnglish (US)
Pages (from-to)424-429
Number of pages6
JournalAmerican journal of orthopedics (Belle Mead, N.J.)
Volume42
Issue number9
StatePublished - Sep 2013

Fingerprint

Knee Replacement Arthroplasties
Venous Thromboembolism
Anticoagulants
Orthopedic Procedures
Safety
Social Adjustment
Enoxaparin
Patient Compliance
Half-Life
Guidelines
Hemorrhage
Incidence
Rivaroxaban

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New anticoagulants for thromboprophylaxis after total knee arthroplasty. / Brown, Timothy S.; Huo, Michael H.

In: American journal of orthopedics (Belle Mead, N.J.), Vol. 42, No. 9, 09.2013, p. 424-429.

Research output: Contribution to journalArticle

@article{7f2855c96baa4226bf08c5bc723af253,
title = "New anticoagulants for thromboprophylaxis after total knee arthroplasty.",
abstract = "Total knee arthroplasty (TKA) is one of the most common orthopedic procedures in the United States. The number of TKAs is expected to rise significantly over the next 2 decades. One of the most common complications after TKA is venous thromboembolism (VTE), which is potentially fatal. The incidence of VTE is effectively reduced by prophylactic anticoagulants, and clinical guidelines have been developed to improve VTE management. However, current anticoagulants have limitations in terms of efficacy, safety, half-life, ease of administration, and patient adherence. Moreover, these anticoagulants require routine monitoring and dose adjustment, and potential bleeding complications represent an important concern. A new generation of anticoagulants, including recently approved rivaroxaban, is being developed to address the shortcomings of current agents. The efficacy and safety of these newer agents are comparable with those of existing ones. Rivaroxaban is the only new oral agent that is approved for use in TKA and that has demonstrated an efficacy superior to that of enoxaparin in phase 3 trials. To optimize the management of VTE prophylaxis after TKAs, orthopedic surgeons must have a thorough understanding of these new oral agents.",
author = "Brown, {Timothy S.} and Huo, {Michael H.}",
year = "2013",
month = "9",
language = "English (US)",
volume = "42",
pages = "424--429",
journal = "American Journal of Orthopedics",
issn = "1078-4519",
publisher = "Quadrant Healthcom Inc.",
number = "9",

}

TY - JOUR

T1 - New anticoagulants for thromboprophylaxis after total knee arthroplasty.

AU - Brown, Timothy S.

AU - Huo, Michael H.

PY - 2013/9

Y1 - 2013/9

N2 - Total knee arthroplasty (TKA) is one of the most common orthopedic procedures in the United States. The number of TKAs is expected to rise significantly over the next 2 decades. One of the most common complications after TKA is venous thromboembolism (VTE), which is potentially fatal. The incidence of VTE is effectively reduced by prophylactic anticoagulants, and clinical guidelines have been developed to improve VTE management. However, current anticoagulants have limitations in terms of efficacy, safety, half-life, ease of administration, and patient adherence. Moreover, these anticoagulants require routine monitoring and dose adjustment, and potential bleeding complications represent an important concern. A new generation of anticoagulants, including recently approved rivaroxaban, is being developed to address the shortcomings of current agents. The efficacy and safety of these newer agents are comparable with those of existing ones. Rivaroxaban is the only new oral agent that is approved for use in TKA and that has demonstrated an efficacy superior to that of enoxaparin in phase 3 trials. To optimize the management of VTE prophylaxis after TKAs, orthopedic surgeons must have a thorough understanding of these new oral agents.

AB - Total knee arthroplasty (TKA) is one of the most common orthopedic procedures in the United States. The number of TKAs is expected to rise significantly over the next 2 decades. One of the most common complications after TKA is venous thromboembolism (VTE), which is potentially fatal. The incidence of VTE is effectively reduced by prophylactic anticoagulants, and clinical guidelines have been developed to improve VTE management. However, current anticoagulants have limitations in terms of efficacy, safety, half-life, ease of administration, and patient adherence. Moreover, these anticoagulants require routine monitoring and dose adjustment, and potential bleeding complications represent an important concern. A new generation of anticoagulants, including recently approved rivaroxaban, is being developed to address the shortcomings of current agents. The efficacy and safety of these newer agents are comparable with those of existing ones. Rivaroxaban is the only new oral agent that is approved for use in TKA and that has demonstrated an efficacy superior to that of enoxaparin in phase 3 trials. To optimize the management of VTE prophylaxis after TKAs, orthopedic surgeons must have a thorough understanding of these new oral agents.

UR - http://www.scopus.com/inward/record.url?scp=84900352172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900352172&partnerID=8YFLogxK

M3 - Article

C2 - 24078968

AN - SCOPUS:84900352172

VL - 42

SP - 424

EP - 429

JO - American Journal of Orthopedics

JF - American Journal of Orthopedics

SN - 1078-4519

IS - 9

ER -